Evaluation of the Relationship Between Hb F Levels and Nucleated Red Blood Cells with Morbidity in Non Transfusion-Dependent Thalassemia Patients

References

• DeBaun MR, Frei-Jones M, Vichinsky E. Thalassemia syndromes. In: Kliegman RM, Stanton BF, St. Geme JW III, et al. Eds. Nelson Textbook of Pediatrics, 19th ed. Philadelphia, PA, USA: Elsevier-Saunders. 2011:1674–1676
   Google Scholar
• Danjou F, Anni F, Galanello R. β-Thalassemia: From genotype to phenotype. Haematologica. 2011;96(11):1573–1575
   PubMed Web of Science ®Google Scholar
• Zuccato C, Breda L, Salvatori F, et al. A combined approach for β-thalassemia based on gene therapy-mediated adult hemoglobin (Hb A) production and fetal hemoglobin (Hb F) induction. Ann Hematol. 2012;91(8):1201–1213
   PubMed Web of Science ®Google Scholar
• Ribeil JA, Arlet JB, Dussiot M, et al. Ineffective erythropoiesis in β-thalassemia. ScientificWorldJournal. 2013;2013:394295. doi: 10.1155/2013/394295
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Weatherall DJ. Red cell disorders. In: Lilleyman JS, Hann IM, Blanchette VS, Eds. Pediatric Haematology, 2nd ed. London, UK: Churchill Livingstone. 2000:307–326
   Google Scholar
• Musallam KM, Taher AT, Rachmilewitz EA. β-Thalassemia intermedia: A clinical perspective. Cold Spring Harb Perspect Med. 2012;2(7):a013482. doi: 10.1101/chsperspect.a013482
   PubMed Web of Science ®Google Scholar
• Musallam KM, Cappellini MD, Wood JC, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica. 2011;96(11):1605–1612
   PubMed Web of Science ®Google Scholar
• Normoblast (Internet). England: (updated December 20 2014; cited February 10 2015). Available from: http://en.wikipedia.org/wiki/Normoblast
   Google Scholar
• Normoblast Information and Courses from MediaLab, Inc. (Internet). (updated 2015; cited February 10 2015). Available from: https://www.medialabinc.net/normoblast-keyword.aspx
   Google Scholar
• Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol. 2007;138(3):291–304
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of β thalassaemia intermedia. Br J Haematol. 2011;152(5):512–523
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Marsella M, Zanforlin N. The natural history of thalassemia intermedia. Ann N Y Acad Sci. 2010;1202:214–220
   PubMed Web of Science ®Google Scholar
• Musallam KM, Cappellini MD, Wood JC, et al. Fetal hemoglobin levels and morbidity in untransfused patients with β-thalassemia intermedia. Blood. 2012;119(2):364–367
   PubMed Web of Science ®Google Scholar
• El-Beshlawy A, Hamdy M, El Ghamrawy M. Fetal globin induction in β-thalassemia. Hemoglobin. 2009;33(1):S197–S203
   PubMedGoogle Scholar
• Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27(7):380–385
   PubMed Web of Science ®Google Scholar
• Goldschmidt N, Spectre G, Brill A, et al. Increased platelet adhesion under flow conditions is induced by both thalassemic platelets and red blood cells. Thromb Haemost. 2008;100(5):864–870
   PubMed Web of Science ®Google Scholar
• Habib A, Kunzelmann C, Shamseddeen W, et al. Elevated levels of circulating procoagulant microparticles in patients with β-thalassemia intermedia. Haematologica. 2008;93(6):941–942
   PubMed Web of Science ®Google Scholar
• Hovav T, Goldfarb A, Artmann G, et al. Enhanced adherence of β-thalassaemic erythrocytes to endothelial cells. Br J Haematol. 1999;106(1):178–181
   PubMed Web of Science ®Google Scholar
• Karimi M, Khanlari M, Rachmilewitz EA. Cerebrovascular accident in β-thalassemia major (β-TM) and β-thalassemia intermedia (β-TI). Am J Hematol. 2008;83(1):77–79
   PubMed Web of Science ®Google Scholar
• Taher A, Isma’eel H, Mehio G, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006;96(4):488–491
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: A multicenter study. Blood. 2001;97(11):3411–3416
   PubMed Web of Science ®Google Scholar
• Amoozgar H, Farhani N, Karimi M. Early echocardiographic findings in β-thalassemia intermedia patients using standard and tissue Doppler methods. Pediatr Cardiol. 2011;32(2):154–159
   PubMed Web of Science ®Google Scholar
• Karimi M, Musallam KM, Cappellini MD, et al. Risk factors for pulmonary hypertension in patients with β thalassemia intermedia. Eur J Intern Med. 2011;22(6):607–610
   PubMed Web of Science ®Google Scholar
• Aessopos A, Kati M, Tsironi M, et al. Exchange blood transfusions for the treatment of leg ulcerations in thalassemia intermedia. Haematologica. 2006;91(5 Suppl):ECR11
   PubMedGoogle Scholar
• Khavari M, Hamidi A, Haghpanah S, et al. Frequency of cholelithiasis in patients with β-thalassemia intermedia with and without hydroxyurea. Iran Red Crescent Med J. 2014;16(7):e18712. doi: 10.5812/ircmj.18712
   Google Scholar
• Al-Allawi NAS, Jalal SD, Mohammad AM, et al. β-Thalassemia intermedia in Northern Iraq: A single center experience. BioMed Res Int. 2014;2014, Article ID 262853, (http://dx.doi.org/10.1155/2014/262853)
   PubMed Web of Science ®Google Scholar
• Yatim NF, Rahim MA, Menon K, et al. Molecular characterization of α- and β-thalassaemia among Malay patients. Int J Mol Sci. 2014;15(5):8835–8845
   PubMed Web of Science ®Google Scholar
• Gasperini D, Perseu L, Melis MA, et al. Heterozygous β-thalassemia with thalassemia intermedia phenotype. Am J Hematol. 1998; 57(1):43–47
   PubMed Web of Science ®Google Scholar
• Cao A, Moi P, Galanello R. Recent advances in β-thalassemias. Pediatr Rep. 2011;3(2):e17. doi: 10.4081/pr.2011.e17
   PubMedGoogle Scholar
• Mohammad AM. Echocardiographic evaluation of thalassemia intermedia patients in Duhok, Iraq. BMC Cardiovasc Disord. 2014;14:183. doi: 10.1186/1471-2261-14-183
   PubMed Web of Science ®Google Scholar
• Sanefuji M, Ohga S, Kira R, et al. Moyamoya syndrome in a splenectomized patient with β-thalassemia intermedia. J Child Neurol. 2006;21(1):75–77
   PubMed Web of Science ®Google Scholar
• Karimi M, Bagheri H, Rastgu F, Rachmilewitz EA. Magnetic resonance imaging to determine the incidence of brain ischaemia in patients with β-thalassaemia intermedia. Thromb Haemost. 2010;103(5):989–993
   PubMed Web of Science ®Google Scholar
• Tantawy AA, El Bablawy N, Adly AA, Ebeid FS. Early predictors of renal dysfunction in Egyptian patients with β-thalassemia major and intermedia. Mediterr J Hematol Infect Dis. 2014;6(1):e2014057. doi: 10.4084/MJHID.2014.057. eCollection 2014
   Google Scholar
• Kurtoglu AU, Kurtoglu E, Temizkan AK. Effect of iron overload on endocrinopathies in patients with β-thalassaemia major and intermedia. Endokrynol Pol. 2012;63(4):260–263
   PubMed Web of Science ®Google Scholar
• Haidar R, Mhaidli H, Taher AT. Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia. Eur Spine J. 2010;19(6):871–878
   PubMed Web of Science ®Google Scholar
• Matin S, Jahromi MG, Karemizadeh Z, et al. The frequency of adrenal insufficiency in adolescents and young adults with thalassemia major versus thalassemia intermedia in Iran. Mediterr J Hematol Infect Dis. 2015;7(1):e2015005. doi: 10.4084/MJHID.2015.005. eCollection 2015
   PubMedGoogle Scholar
• Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: The OPTIMAL CARE study. Blood. 2010;115(10):1886–1892
   PubMed Web of Science ®Google Scholar
• Karimi M, Haghpanah S, Bagheri MH, et al. Frequency and distribution of asymptomatic brain lesions in patients with β-thalassemia intermedia. Ann Hematol. 2012;91(12):1833–1838
   PubMed Web of Science ®Google Scholar
• Dumitru I. Heart failure (Internet). (updated: June 9 2014; cited February 13 2015]. Available from http://emedicine.medscape.com/article/163062-overview
   Google Scholar
• Collins SP, Lindsell CJ, Yealy DM, et al. A comparison of criterion standard methods to diagnose acute heart failure. Congest Heart Fail. 2012;18(5):262–271
   PubMedGoogle Scholar
• Bethel M. Osteoporosis (Internet). [updated: February 26 2015; cited March 24 2015]. Available from http://emedicine.medscape.com/article/330598-overview
   Google Scholar
• Musallam KM, Cappellini M, Daar S, et al. Serum ferritin level and morbidity risk in transfusion-independent patients with β-thalassemia intermedia: The ORIENT study. Haematologica. 2014;99(11):e218–e221
   PubMed Web of Science ®Google Scholar
• Patrinos GP, Grosveld FG. Pharmacogenomics and therapeutics of hemoglobinopathies. Hemoglobin. 2008;32(1-2):229–236
   PubMed Web of Science ®Google Scholar
• Borg J, Phylactides M, Bartsakoulia M, et al. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients. Pharmacogenomics. 2012;13(13):1487–1500
   PubMed Web of Science ®Google Scholar
• Atweh GF, DeSimone J, Saunthararajah Y, et al. Hemoglobinopathies. Hematology Am Soc Hematol Educ Program. 2003:14–39
   PubMedGoogle Scholar
• Banan M, Bayat H, Azarkeivan A, et al. The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients. Hemoglobin. 2012;36(4):371–380
   PubMed Web of Science ®Google Scholar